PDF Publication Title:
Text from PDF Page: 013
Cancers 2018, 10, 144 13 of 15 4.7. Clonogenic Survival Assay A clonogenic survival assay was performed according to a previous publication [43]. Mouse 4T1 TNBC cells were treated with DMSO, TMZ, or OAdmCherry alone or in combination at indicated concentrations; 24 h post treatment, the cells were trypsinized and plated at a cell density of 1 × 103 per well in a 6-well plate. The cells were cultured for 10 days, fixed with 3.7% paraformaldehyde, and stained with 1% crystal violet. Colonies with ≥50 cells were counted. The plating efficiency was calculated for each condition, with the surviving fraction calculated relative to the untreated control, as described previously [43–45]. 4.8. Statistical Analysis One- and two-way ANOVA was used to determine differences in cell viability across different treatments. Statistical differences between combined treatments (TMZ/OAdmCherry) and either agent alone were determined by the significance of the interaction effect of the dose and virus. Differences in cell viability across combination therapies were analyzed by one-way ANOVA. Post hoc testing was performed with Tukey’s adjustment to control for a significance level of 0.05. Author Contributions: R.G.-M. and R.G.-R. performed the experiments and wrote the paper; L.R.M., K.M.M., R.M.d.O.-L., and J.G.G.-G. conceived and designed the experiments and edited the manuscript; L.R.M., A.C., and J.G.G.-G. analyzed the data; R.G.-M., L.R.M., and J.G.G.-G. revised the manuscript. Acknowledgments: This work was supported by the National Institutes of Health NCI awards R25CA134283 (R.G.-R), R21CA210202 (J.G.G.-G.), and R01 EB020135 (L.R.M). We thank Margaret Abby for editing. Conflicts of Interest: The authors declare no conflict of interest. References 1. Harbeck, N.; Gnant, M. Breast cancer. Lancet 2017, 389, 1134–1150. [CrossRef] 2. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363, 1938–1948. [CrossRef] [PubMed] 3. Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016, 13, 674–690. [CrossRef] [PubMed] 4. Darb-Esfahani, S.; Loibl, S.; Muller, B.M.; Roller, M.; Denkert, C.; Komor, M.; Schluns, K.; Blohmer, J.U.; Budczies, J.; Gerber, B.; et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: Role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009, 11, R69. [CrossRef] [PubMed] 5. Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275–1281. [CrossRef] [PubMed] 6. Bonotto, M.; Gerratana, L.; Poletto, E.; Driol, P.; Giangreco, M.; Russo, S.; Minisini, A.M.; Andreetta, C.; Mansutti, M.; Pisa, F.E.; et al. Measures of outcome in metastatic breast cancer: Insights from a real-world scenario. Oncologist 2014, 19, 608–615. [CrossRef] [PubMed] 7. Liu, T.C.; Thorne, S.H.; Kirn, D.H. Oncolytic adenoviruses for cancer gene therapy. Methods Mol. Biol. 2008, 433, 243–258. [PubMed] 8. Liu, T.C.; Hwang, T.H.; Bell, J.C.; Kirn, D.H. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: A high-value iterative loop. Mol. Ther. 2008, 16, 1006–1008. [CrossRef] [PubMed] 9. Heise, C.; Sampson-Johannes, A.; Williams, A.; McCormick, F.; Von Hoff, D.D.; Kirn, D.H. ONYX-015, an e1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997, 3, 639–645. [CrossRef] [PubMed]PDF Image | Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy
PDF Search Title:
Temozolomide Enhances Triple-Negative Breast Cancer VirotherapyOriginal File Name Searched:
cancers-10-00144.pdfDIY PDF Search: Google It | Yahoo | Bing
Cruise Ship Reviews | Luxury Resort | Jet | Yacht | and Travel Tech More Info
Cruising Review Topics and Articles More Info
Software based on Filemaker for the travel industry More Info
The Burgenstock Resort: Reviews on CruisingReview website... More Info
Resort Reviews: World Class resorts... More Info
The Riffelalp Resort: Reviews on CruisingReview website... More Info
CONTACT TEL: 608-238-6001 Email: greg@cruisingreview.com (Standard Web Page)